Quantum BioPharma Executive Discussed Clinical Pipeline
Anthony Durkacz detailed the status of multiple sclerosis drug Lucid-MS and the unbuzzd IPO process.
Updated on Sept. 30, 2026 in Biotech
Live Poll
Do you believe pharmaceutical companies are successfully developing better treatments for chronic conditions?
Quantum BioPharma executive Anthony Durkacz appeared on a new episode of The BioMedWire Podcast to discuss the firm's medical developments. The discussion covered the upcoming Phase 2 clinical trials for the multiple sclerosis treatment Lucid-MS and the ongoing IPO process for unbuzzd.
Why it matters
The podcast appearance provides transparency regarding Quantum BioPharma's clinical pipeline and the financial structure of its subsidiary stakes. These updates help investors and stakeholders understand the progress of therapeutic targets and the company's long-term revenue streams.
Quantum BioPharma owns approximately 20% of unbuzzd and receives a 7% royalty on sales. This royalty rate is set to drop to 3% once cumulative sales reach the $250 million threshold.
The players
Anthony Durkacz
He is an executive at Quantum BioPharma Ltd. who recently discussed company pipeline projects on The BioMedWire Podcast.
Quantum BioPharma Ltd.
This biotechnology firm is currently developing Lucid-MS as a novel treatment for multiple sclerosis.
IBN
Headquartered in Austin, this media company provides syndication services to over 500 companies, including the production of The BioMedWire Podcast.
The details
Quantum BioPharma is currently moving its Lucid-MS treatment into Phase 2 clinical trials, with a focus on targeting myelin to prevent and reverse degradation. Meanwhile, the company continues its involvement with unbuzzd, which was the subject of a peer-reviewed study published in March 2026.
Timeline
A peer-reviewed journal published a study regarding unbuzzd in March 2026.
Quantum BioPharma held a 19.48% ownership stake in unbuzzd as of June 30, 2026.
IBN released the new podcast episode featuring Anthony Durkacz on September 30, 2026.
Market Landscape
The transition of the Lucid-MS myelin-targeting therapeutic program into Phase 2 trials marks a significant shift in the competitive landscape for multiple sclerosis treatments. This progress places Quantum BioPharma in a key position as it simultaneously navigates the public listing of its affiliate, unbuzzd.
Investors and those tracking the biotechnology sector can use these updates to evaluate the progress of ongoing clinical trials and the financial implications of upcoming IPO activity. These disclosures offer clarity on how Quantum BioPharma's royalty structures might influence future valuation.
The takeaway
Clinical trial milestones and strategic IPO processes are key indicators for the long-term growth of biotechnology firms. Stakeholders should monitor upcoming marketing launches and financial benchmarks to track the actualized value of current drug pipelines.
Further reading
Learn more about the latest industry developments in our Biotech section.
More information
To hear the full conversation and catch up on the latest company updates, Listen to the BioMedWire podcast.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe pharmaceutical companies are successfully developing better treatments for chronic conditions?
